# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JMP Securities analyst Jonathan Wolleben reiterates Larimar Therapeutics (NASDAQ:LRMR) with a Market Outperform and maintain...
START is a new milestone-driven program designed to accelerate development of novel therapies intended to address an unmet medi...
Citigroup analyst Samantha Semenkow maintains Larimar Therapeutics (NASDAQ:LRMR) with a Buy and raises the price target from...
Larimar Therapeutics announces FDA lift of partial clinical hold on nomlabofusp (CTI-1601) for Friedreich's Ataxia. Data fr...